"Receptor, IGF Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
| Descriptor ID |
D017526
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.185 D12.776.543.750.630.468 D12.776.543.750.750.400.780.400
|
| Concept/Terms |
Receptor, IGF Type 1- Receptor, IGF Type 1
- Receptors, IGF-1
- IGF-1 Receptors
- Receptors, IGF 1
- IGF-1 Receptor
- IGF 1 Receptor
- Receptor, IGF-1
- Receptors, Insulin-Like-Growth Factor I
- IGF-I Receptor
- IGF I Receptor
- Receptor, Insulin-Like Growth Factor Type 1
- Receptor, IGF-I
- Receptor, IGF I
- Receptor, Insulin-Like Growth Factor I
- Insulin-Like-Growth Factor I Receptor
- Insulin Like Growth Factor I Receptor
- IGF Type 1 Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, IGF Type 1".
Below are MeSH descriptors whose meaning is more specific than "Receptor, IGF Type 1".
This graph shows the total number of publications written about "Receptor, IGF Type 1" by people in this website by year, and whether "Receptor, IGF Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, IGF Type 1" by people in Profiles.
-
CXCR4 mediates the effects of IGF-1R signaling in rodent bone homeostasis and fracture repair. Bone. 2023 01; 166:116600.
-
The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.
-
Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
-
Role of Runx2 in IGF-1R?/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene. 2016 09 08; 35(36):4730-40.
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34.
-
Future directions for pediatric and young adult bone sarcoma. Curr Probl Cancer. 2013 Jul-Aug; 37(4):225-35.
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
-
Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys. Birth Defects Res B Dev Reprod Toxicol. 2010 Aug; 89(4):326-38.
-
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94.
-
Methylation of the OP-1 promoter: potential role in the age-related decline in OP-1 expression in cartilage. Osteoarthritis Cartilage. 2009 Apr; 17(4):513-7.